(Q39051716)

English

Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial

scientific article published on 21 January 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

phase II clinical trial

0 references

1 reference

ChEBI release 2020-05-28

carcinoma of unknown primary

1 reference

based on heuristic

inferred from title

Gedske Daugaard

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

John D Hainsworth

1

object named as

John D Hainsworth

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

author name string

Thierry Lesimple

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Gerdt Hübner

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

F Anthony Greco

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Michael J Stahl

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Christian Meyer Zum Büschenfelde

7

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Djelila Allouache

8

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Nicolas Penel

9

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Poul Knoblauch

10

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Karim S Fizazi

11

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

language of work or name

0 references

publication date

21 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

121

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1654-1661

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Carcinomas of an unknown primary origin--diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Histone deacetylase inhibitors in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Development of histone deacetylase inhibitors for cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

21 January 2018

Histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

7 January 2021

based on heuristic

inferred from DOI database lookup

Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29229

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.29229

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39051716&oldid=1806044658"